Metabolic syndrome in people with schizophrenia: a review

@article{Hert2009MetabolicSI,
  title={Metabolic syndrome in people with schizophrenia: a review},
  author={Marc De Hert and Vincent Schreurs and Davy Vancampfort and Ruud Van Winkel},
  journal={World Psychiatry},
  year={2009},
  volume={8}
}
Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with schizophrenia. Patients are at risk for premature mortality and overall have limited access to physical health care. In part these cardio-metabolic risk factors are attributable to unhealthy lifestyle, including poor diet and sedentary behaviour. But over recent years it has become apparent that antipsychotic agents can have a negative impact on some of the modifiable risk factors. The psychiatrist… Expand
Schizophrenia: Metabolic Consequences
TLDR
Over recent years, international organizations have developed screening and monitoring guidelines in order to reduce modifiable risk factors, comorbidity, and mortality rates among patients affected by schizophrenia and improve the outcome of illness, including patients' functioning and quality of life. Expand
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management
TLDR
This paper is a review of current knowledge about the metabolic issues of patients affected by schizophrenia and describes clinical characteristics and medical management strategies for such conditions. Expand
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
TLDR
This work provides an overview specifically addressing why patients with schizophrenia are at increased risk for metabolic problems, how commonly used antipsychotic medications vary in terms of their metabolic liability, and how to effectively screen for and monitor metabolic problems in patients receiving antipsychotics. Expand
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
TLDR
These guidelines review issues surrounding monitoring of physical health risk factors and make recommendations about an appropriate approach to interventions for people experiencing weight gain when taking antipsychotic medications. Expand
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses.
TLDR
The mechanisms by which schizophrenia and patients with severe mental illness are susceptible to cardiometabolic disorders are complex and include lifestyle risks and direct and indirect effects of antipsychotic drugs. Expand
The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review
TLDR
This review aims to update the reader with the latest knowledge about the prevalence of MetS in schizophrenia and what might be the underlying pathophysiological mechanisms. Expand
Metabolic syndrome in severe mental disorders.
TLDR
The obstacles to the implementation of the available guidelines for monitoring metabolic effects and changing unhelpful lifestyles need to be overcome by making monitoring mandatory and integration of physical exercise into routine care. Expand
Metabolic disturbances in schizophrenia: Association with disease and drugs
TLDR
Regular screening of metabolic parameters in schizophrenia patients and treatment of these complications is equally important and multi-disciplinary approach may be more beneficial in detecting and managing these complications. Expand
Metabolic syndrome with the atypical antipsychotics.
TLDR
In addition to behavioral therapy, emerging data suggest that pharmacological therapy, most notably metformin, is efficacious in the treatment and possibly prevention of SGA-associated metabolic derangements. Expand
Metabolic syndrome in patients with schizophrenia
TLDR
The psychiatrist is especially responsible for the patient’s health and this responsibility should be represented by the readiness to cooperate with other physicians, as well as to imply specialist diagno. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 231 REFERENCES
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
TLDR
A framework for the assessment, monitoring and management of patients with schizophrenia in the UK clinical setting is recommended and it is demonstrated that treatment-related metabolic disturbances are commonplace in this patient group and that the use of certain second-generation antipsychotics may compound the risk of developing the metabolic syndrome and CVD. Expand
Schizophrenia and comorbid metabolic disorders.
TLDR
B baseline screening and routine monitoring of patient weight, fasting lipid profile, and fasting plasma glucose are essential and optimal treatment for patients with schizophrenia and comorbid metabolic disorders is best achieved when all parties involved with patient care communicate and work together. Expand
Metabolic syndrome and mental illness.
  • J. Newcomer
  • Medicine
  • The American journal of managed care
  • 2007
TLDR
Screen and regular monitoring of metabolic parameters such as weight, waist circumference, plasma glucose and lipids, and blood pressure are recommended to manage risk in patients with major mental illness and steps for risk reduction are described. Expand
Metabolic syndrome: epidemiology and consequences.
  • F. Sacks
  • Medicine
  • The Journal of clinical psychiatry
  • 2004
TLDR
The articles in this supplement review how obesity, diabetes, and dyslipidemia play a role in the treatment of schizophrenia, but these issues are by no means limited to schizophrenia. Expand
Antipsychotic medications: metabolic and cardiovascular risk.
  • J. Newcomer
  • Medicine
  • The Journal of clinical psychiatry
  • 2007
TLDR
Evidence from large clinical samples indicates a high prevalence of metabolic syndrome and all of its components in persons with serious mental illness, particularly in patients with schizophrenia, as well as with an increased risk of diabetes and dyslipidemia. Expand
Physical consequences of schizophrenia and its treatment: the metabolic syndrome.
TLDR
This minireview aims to explore the potential role of issues and medication in terms of the increased morbidity and mortality observed in schizophrenia. Expand
Implementation of monitoring and management guidelines for second-generation antipsychotics.
  • M. Sernyak
  • Medicine
  • The Journal of clinical psychiatry
  • 2007
It has long been known that psychiatric patients experience increased morbidity and mortality associated with a range of physical disorders. Lifestyle, inadequate health care, and a variety of otherExpand
Metabolic Monitoring for Patients Treated with Antipsychotic Medications
  • T. Cohn, M. Sernyak
  • Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2006
TLDR
Clinicians are encouraged to adopt a structured system for conducting and recording metabolic monitoring and to develop collaborations with family physicians, diabetes specialists, dieticians, and recreation therapists to facilitate appropriate medical care for antipsychotic-treated patients. Expand
Do guidelines for severe mental illness promote physical health and well-being?
TLDR
Clear and consistent recommendations on how and when to monitor weight, cardiovascular function, and metabolic parameters and, importantly, what to do with the results, would support clinicians wishing to integrate physical and mental healthcare. Expand
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
TLDR
The metabolic syndrome is highly prevalent among treated patients with schizophrenia and should be part of the clinical management of patients treated with antipsychotics, according to the authors. Expand
...
1
2
3
4
5
...